Dr. Jack West reviews the potential new role for immunotherapy in locally advanced NSCLC based on the early report that the PACIFIC trial of durvalumab after chemo/radiation is positive for a significant improvement in progression-free survival.
Importing Immunotherapy into the Curative Setting for NSCLC: The Potential Implications of the PACIFIC Trial (BMIC-001)
